Loading
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.
Latest quote
$30.47
+$0.21 · +0.69%
After-hours
$30.47
$0.00 · 0.00%
Oct 9, 4:38 PM ET
Regular session · ET · Market data may be delayed.
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.
Day range
Current $30.47
52-week range
Current $30.47
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
33
Expensive
Sentiment
53
Mixed
Risk
31
Moderate Risk
Momentum
71
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.
Day range
Current $30.47
52-week range
Current $30.47
Operating income
Net income
| Metric (USD) | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Cost of goods sold | 409K USD | — | — | — | — |
| Gross profit | −409K USD | — | — | — | — |
| Research and development | 456.66M USD | 360.92M USD | 212.93M USD | 160.26M USD | 101.81M USD |
| Selling, general, and administrative | 76.24M USD | 77.24M USD | 57.28M USD | 48.02M USD | 54.23M USD |
| Operating expenses | 532.9M USD | 438.15M USD | 270.21M USD | 208.28M USD | 156.03M USD |
| Interest income | 25.33M USD | 24.73M USD | 24.95M USD | 7.58M USD | — |
| Interest expense | — | — | — | 12.48M USD | — |
| Depreciation and amortization | 409K USD | 377K USD | 231K USD | 193K USD | 126K USD |
| Operating income | −532.9M USD | −438.15M USD | −270.21M USD | −208.28M USD | −156.03M USD |
| Net income | −505.61M USD | −413.84M USD | −259.34M USD | −210.96M USD | −156.73M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$40.00
31.28% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI106.46M0.00%2.3T USD0.03%$381.94+0.63%
Vanguard Morningstar Small-Cap ETFVB77.08M0.04%185.3B USD0.03%$289.48+0.64%
iShares Russell 2000 ETFIWM69.26M0.09%77.7B USD0.19%$278.94+0.49%
State Street SPDR S&P Biotech ETFXBI66.16M0.65%10.11B USD0.35%$153.77+3.00%
Vanguard Morningstar Small-Cap Growth ETFVBK44.37M0.10%44.7B USD0.05%$344.74+1.22%
Vanguard Extended Market ETFVXF36.62M0.04%95.4B USD0.05%$235+0.80%
iShares Russell 2000 Growth ETFIWO24.15M0.18%14.04B USD0.24%$356.78+0.94%
Vanguard Russell 2000 ETFVTWO20.02M0.11%18B USD0.06%$112.66+0.50%Vanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
